Exclusion criteria: The research articles published before 2018 on SGLT2 inhibitors and cardiovascular diseases were limited, as they were not the main focus, were often not published in English, had very small study populations, and were restricted to specific geographic areas. This evidence concerns the gene SLC5A2 and cardiovascular disorder.